Synlait Milk Limited

Synlait Milk Limited

SMLKF
Synlait Milk LimitedUS flagOther OTC
0.97
USD
-NaN
- -
585.71MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
- -
4.38
4.9
5.72
7.26
6.62
7.6
6.04
7.49
- -
Basic EPS, GAAP
0.19
0.13
0.07
0.23
0.22
0.42
0.46
0.42
-0.14
0.18
-0.02
-0.83
- -
Free Cash Flow per Basic Share
-0.36
-0.26
-0.61
-0.27
0.47
-0.67
-1.79
-0.85
-0.68
-0.43
-0.3
-0.14
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.62
1.17
1.24
1.47
2.06
2.42
2.88
3.31
3.67
3.65
3.63
2.79
- -
Tangible Book Value per Share
2.65
1.18
1.11
1.67
2.23
2.29
2.64
2.78
3.11
2.7
3.23
2.15
- -
Basic Weighted Avg Shares
60
151
151
151
173
179
179
179
207
219
219
219
539
Sales/Revenue/Turnover
- -
- -
- -
- -
759
879
1,024
1,302
1,367
1,661
1,321
1,637
- -
Operating Margin (%)
- -
- -
- -
- -
8.65
12.77
12.12
9.56
-1.78
3.11
-0.52
-5.27
- -
Depreciation Expense
- -
- -
- -
- -
23
26
28
48
58
57
64
72
- -
Net Income, GAAP
12
20
11
34
38
75
82
75
-28
39
-4
-182
- -
Effective Tax Rate (%)
28.07
27.65
30.27
28.95
28.64
28.18
28.54
26.2
- -
7.42
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
5.04
8.48
8.03
5.78
-2.08
2.32
-0.32
-11.13
- -
Working Capital
-11
-11
-63
29
26
3
-90
2
142
-72
-62
-236
- -
LT Debt
28
91
178
169
84
97
249
442
471
320
221
239
- -
Total Equity
164
183
172
257
393
425
492
606
767
748
790
605
- -
Return on Invested Capital (%)
- -
- -
- -
- -
8.95
13.88
12.08
8.96
- -
3.98
- -
- -
- -
Return on Capital (%)
- -
8.14
4.33
10.05
9.77
14.82
12.24
8.91
- -
4.48
- -
- -
- -
Return on Common Equity (%)
- -
11.7
5.78
16.78
13.22
18.86
17.29
13.56
-4.21
4.95
-0.54
-25.96
- -

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,321
2024
- -
- -
- -
- -
1,637
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
-0.83
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Richard Wyeth
Full Time Employees
560
Sector
Consumer Defensive
Industry
Packaged Foods
Address
1028 Heslerton Road Rakaia New Zealand 7783
IPO Date
Nov 9, 2021
Business
Synlait Milk Limited Synlait Milk Limited is a New Zealand-based dairy processor that manufactures and sells nutritional dairy and plant-based products, including infant formula, advanced nutrition powders, UHT cream, whole milk powders, lactoferrin, and specialized ingredients to multinational customers worldwide; it also produces consumer dairy products through subsidiaries Dairyworks and Talbot Forest Cheese, alongside foodservice items such as fresh milk and cream from its advanced liquid dairy packaging facility. Headquartered in Dunsandel, Canterbury, with manufacturing sites in Auckland and Pōkeno, a research and development center in Palmerston North, and offices in Beijing and Shanghai, the company sources milk from over 280 suppliers in Canterbury and Waikato regions and operates across China, Southeast Asia, the Middle East, Australia, New Zealand, the Americas, and the European Union. Founded in 2000 by dairy farmers including Dr. John Penno through the purchase of Robindale Farm, Synlait shifted from farming to processing by 2008 with its first Dunsandel plant and listed on the NZX in 2013 under ticker SML and ASX in 2016 under SM1. In recent developments, Bright Dairy increased its ownership to a controlling 65% stake via a 2024 recapitalisation involving $185 million for new shares, while a2 Milk Company maintained its approximately 20% holding with a $33 million investment, enabling debt repayment and financial stabilization amid profitability pressures. Additionally, Synlait secured regulatory approval in 2025 for the $178 million sale of its North Island assets, including Pokeno and Auckland facilities, to Abbott Laboratories, marking a strategic pivot to focus on advanced nutrition powders and foodservice products while reducing debt and streamlining operations.

Company News

APIChat
  • Synlait Milk Limited (SMLKF) Q2 2026 Earnings Call Transcript

  • Synlait Milk Limited (SMLKF) Shareholder/Analyst Call Transcript